Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.0700
- TODAY'S CHANGE (%)-0.0400 (-1.2862%)
- Bid / Lots3.0100/ 50
- Ask / Lots3.1400/ 12
- Open / Previous Close3.1500 / 3.1100
- Day Range
- 52 Week Range
- Volume128,295
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 1985 | 3.14 |
| 09:34 ET | 300 | 3.11 |
| 09:36 ET | 200 | 3.11 |
| 09:45 ET | 854 | 3.15 |
| 09:50 ET | 300 | 3.13 |
| 09:59 ET | 1716 | 3.08 |
| 10:03 ET | 400 | 3.085 |
| 10:08 ET | 100 | 3.07 |
| 10:14 ET | 600 | 3.0703 |
| 10:15 ET | 100 | 3.075 |
| 10:17 ET | 202 | 3.075 |
| 10:24 ET | 610 | 3.085 |
| 10:26 ET | 103 | 3.08 |
| 10:32 ET | 100 | 3.09 |
| 10:35 ET | 1189 | 3.07 |
| 10:37 ET | 250 | 3.0797 |
| 10:53 ET | 100 | 3.07 |
| 11:00 ET | 100 | 3.0709 |
| 11:02 ET | 100 | 3.08 |
| 11:04 ET | 300 | 3.08 |
| 11:06 ET | 413 | 3.09 |
| 11:11 ET | 100 | 3.1002 |
| 11:15 ET | 340 | 3.12 |
| 11:20 ET | 1282 | 3.1197 |
| 11:22 ET | 100 | 3.1 |
| 11:24 ET | 400 | 3.11 |
| 11:29 ET | 100 | 3.1102 |
| 11:33 ET | 100 | 3.1 |
| 11:40 ET | 771 | 3.1 |
| 11:44 ET | 212 | 3.0901 |
| 11:47 ET | 200 | 3.1092 |
| 11:49 ET | 100 | 3.105 |
| 11:51 ET | 200 | 3.1 |
| 11:56 ET | 100 | 3.09 |
| 11:58 ET | 3300 | 3.1035 |
| 12:02 ET | 100 | 3.105 |
| 12:07 ET | 1193 | 3.12 |
| 12:12 ET | 109 | 3.13 |
| 12:14 ET | 125 | 3.13 |
| 12:16 ET | 200 | 3.11 |
| 12:30 ET | 1155 | 3.13 |
| 12:32 ET | 200 | 3.1195 |
| 12:38 ET | 100 | 3.11 |
| 12:48 ET | 100 | 3.12 |
| 12:50 ET | 200 | 3.11 |
| 12:56 ET | 100 | 3.12 |
| 12:59 ET | 409 | 3.1 |
| 01:03 ET | 299 | 3.091 |
| 01:10 ET | 200 | 3.09 |
| 01:12 ET | 100 | 3.09 |
| 01:19 ET | 200 | 3.11 |
| 01:24 ET | 101 | 3.11 |
| 01:30 ET | 100 | 3.11 |
| 01:33 ET | 100 | 3.1 |
| 01:48 ET | 200 | 3.11 |
| 01:50 ET | 100 | 3.09 |
| 01:51 ET | 2032 | 3.085 |
| 01:53 ET | 100 | 3.1 |
| 01:57 ET | 900 | 3.11 |
| 02:04 ET | 200 | 3.1 |
| 02:08 ET | 100 | 3.1 |
| 02:09 ET | 500 | 3.09 |
| 02:20 ET | 200 | 3.1 |
| 02:26 ET | 200 | 3.09 |
| 02:29 ET | 100 | 3.08 |
| 02:31 ET | 2474 | 3.07 |
| 02:33 ET | 400 | 3.07 |
| 02:36 ET | 200 | 3.065 |
| 02:38 ET | 1100 | 3.0618 |
| 02:40 ET | 1350 | 3.065 |
| 02:42 ET | 2405 | 3.07 |
| 02:56 ET | 100 | 3.07 |
| 03:00 ET | 2109 | 3.055 |
| 03:02 ET | 400 | 3.055 |
| 03:03 ET | 1862 | 3.05 |
| 03:07 ET | 100 | 3.05 |
| 03:21 ET | 200 | 3.05 |
| 03:23 ET | 100 | 3.06 |
| 03:25 ET | 3663 | 3.04 |
| 03:34 ET | 200 | 3.05 |
| 03:36 ET | 100 | 3.04 |
| 03:39 ET | 158 | 3.05 |
| 03:45 ET | 2168 | 3.045 |
| 03:48 ET | 4665 | 3.045 |
| 03:52 ET | 1465 | 3.05 |
| 03:54 ET | 6432 | 3.05 |
| 03:56 ET | 1650 | 3.065 |
| 03:57 ET | 6074 | 3.08 |
| 03:59 ET | 8391 | 3.07 |
May 15, 2024
*DJ Kodiak Sciences 1Q Loss/Shr 82c >KOD, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow JonesKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy, from 7:32PM ET on Monday May 13, 2024 by Dow Jones
7:32PM ET on Monday May 13, 2024 by Dow Jones
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 161.3M | -0.7x | --- |
X4 Pharmaceuticals Inc | 151.7M | -1.3x | --- |
Cardiff Oncology Inc | 153.9M | -3.8x | --- |
Context Therapeutics Inc | 150.0M | -1.5x | --- |
Greenwich Lifesciences Inc | 172.6M | -19.4x | --- |
Trevi Therapeutics Inc | 176.1M | -7.4x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $161.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.41 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
